DaVita Inc. $DVA Stake Raised by Andra AP fonden

Andra AP fonden increased its holdings in DaVita Inc. (NYSE:DVA) by 2.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 236,584 shares of the company’s stock after purchasing an additional 5,400 shares during the quarter. Andra AP fonden’s holdings in DaVita were worth $31,435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. Man Group plc boosted its position in DaVita by 1,608.6% during the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after acquiring an additional 269,081 shares during the period. Norges Bank acquired a new stake in DaVita in the second quarter worth about $32,986,000. Todd Asset Management LLC bought a new position in DaVita in the 3rd quarter valued at about $21,842,000. Arrowstreet Capital Limited Partnership increased its stake in DaVita by 132.1% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock valued at $37,619,000 after buying an additional 150,318 shares during the period. Finally, Rakuten Investment Management Inc. bought a new stake in shares of DaVita in the 3rd quarter worth $19,875,000. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on DVA shares. UBS Group increased their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. Truist Financial set a $158.00 price objective on DaVita in a research report on Thursday, February 5th. TD Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Finally, Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $155.80.

DaVita Stock Performance

DVA opened at $152.77 on Friday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $157.12. The firm’s 50-day simple moving average is $123.36 and its 200-day simple moving average is $125.82. The firm has a market cap of $10.21 billion, a price-to-earnings ratio of 15.42, a PEG ratio of 0.52 and a beta of 0.99.

DaVita (NYSE:DVA) last announced its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.DaVita’s revenue was up 9.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, sell-side analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.